cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Bristol Myers Squibb Co
134 own
74 watching
Current Price
$72.45
$-0.54
(-0.74%)
logo-bmy
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
154,040.32M
52-Week High
52-Week High
81.435
52-Week Low
52-Week Low
62.9
Average Volume
Average Volume
5.43M
Dividend Yield
Dividend Yield
0.032969
P/E Ratio
P/E Ratio
16.83
iconMarket Capitalization154,040.32M
icon52-Week High81.435
icon52-Week Low62.9
iconAverage Volume5.43M
iconDividend Yield0.032969
iconP/E Ratio16.83
What does the Bristol Myers Squibb Co do?
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection (HIV). Its products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma. The company's products also comprise Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation; Baraclude to treat chronic hepatitis B virus; Daklinza and Sunvepra to treat hepatitis C virus (HCV); Reyataz and Sustiva to treat HIV; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; and Orencia to treat rheumatoid arthritis. It has collaborations with Portola Pharmaceuticals, Inc. to develop and commercialize andexanet alfa, an investigational agent; Apexigen, Inc. to evaluate Opdivo in combination with APX005M in patients with solid tumors; and license agreement with Nitto Denko Corporation to develop and commercialize siRNA molecules targeted at HSP47 in vitamin A. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Read More
How much money does Bristol Myers Squibb Co make?
News & Events about Bristol Myers Squibb Co.
Accesswire
1day ago
NORTHAMPTON, MA / ACCESSWIRE / January 27, 2023 / Originally published on Bristol Myers Squibb News & PerspectivesA decade ago, the evolution of immuno-oncology transformed the landscape of therapy for patients with many cancers. Although individual immunotherapies have helped to improve...
Business Wire
1day ago
Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval of Reblozyl (luspatercept) as a treatment for adult patients with anemia associated with nontransfusion-dependent (NTD) beta...
Business Wire
1day ago
Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Sotyktu (deucravacitinib) for the treatment of adults with moderate-to-severe plaque psoriasis. Sotyktu, an oral...
Globe Newswire
2days ago
LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- iVexSol Inc., a technology-based lentiviral vector (LVV) contract development and manufacturing organization (CDMO), announced $23.8 million in Series A-3 funding. New investors Bristol Myers Squibb (NYSE: BMY), Charles River Laboratories (NYSE: ...
Accesswire
9days ago
Amgen Joins Gilead Sciences as a Program SupporterApplications Now Open for Physicians and Medical StudentsOriginally published on Bristol Myers Squibb News & PerspectivesPRINCETON, NJ / ACCESSWIRE / January 19, 2023 / The Robert A. Winn Diversity in Clinical Trials Award Program (Winn...
Frequently Asked Questions
Frequently Asked Questions
What is Bristol Myers Squibb Co share price today?
plus_minus_icon
Can Indians buy Bristol Myers Squibb Co shares?
plus_minus_icon
How can I buy Bristol Myers Squibb Co shares from India?
plus_minus_icon
Can Fractional shares of Bristol Myers Squibb Co be purchased?
plus_minus_icon
What are the documents required to start investing in Bristol Myers Squibb Co stocks?
plus_minus_icon
What is today’s traded volume of Bristol Myers Squibb Co?
plus_minus_icon
What is today’s market capitalisation of Bristol Myers Squibb Co?
plus_minus_icon
What is the 52-Week High and Low Range of Bristol Myers Squibb Co?
plus_minus_icon
What percentage is Bristol Myers Squibb Co down from its 52-Week High?
plus_minus_icon
What percentage is Bristol Myers Squibb Co up from its 52-Week Low?
plus_minus_icon
Current Price
$72.45
$-0.54
(-0.74%)
logo-bmy
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Novartis AG
Novartis AG
$89.49
$-0.35 (-0.39 %)
Merck & Co. Inc.
Merck & Co. Inc.
$105.38
$-1.49 (-1.39 %)
Johnson & Johnson
Johnson & Johnson
$168.23
$-0.66 (-0.39 %)
AstraZeneca PLC
AstraZeneca PLC
$65.53
$-0.46 (-0.70 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Novartis AG
Novartis AG
$89.49
$-0.35 (-0.39 %)
Merck & Co. Inc.
Merck & Co. Inc.
$105.38
$-1.49 (-1.39 %)
Johnson & Johnson
Johnson & Johnson
$168.23
$-0.66 (-0.39 %)
AstraZeneca PLC
AstraZeneca PLC
$65.53
$-0.46 (-0.70 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00